search
Back to results

The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women

Primary Purpose

Infertility, Female

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Inofolic Plus
Sponsored by
Palm Beach Center for Reproductive Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Female focused on measuring female fertility, ovarian reserve, oocyte quality, oocyte quantity, antimullerian hormone, AMH, dietary supplements, inofolic plus, myoinositol, folic acid

Eligibility Criteria

18 Years - 42 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female between 18 - 42 years of age
  • Diagnosed with "Diminished Ovarian Reserve" (DOR)

Exclusion Criteria:

  • Ongoing history of illicit drug or tobacco use
  • Ovarian surgery within 90 days of signing the consent form

Sites / Locations

  • Palm Beach Center for Reproductive Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Inofolic Plus

Arm Description

Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.

Outcomes

Primary Outcome Measures

Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve (AMH Levels)
Women will receive Infolic Plus nightly for up to 90 days. Baseline AMH blood levels will be analyzed, and AMH titers will be checked monthly thereafter for the 90 day duration of the study.

Secondary Outcome Measures

Full Information

First Posted
February 3, 2011
Last Updated
May 24, 2012
Sponsor
Palm Beach Center for Reproductive Medicine
Collaborators
Lo.Li. Pharma, Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01290432
Brief Title
The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women
Official Title
The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Palm Beach Center for Reproductive Medicine
Collaborators
Lo.Li. Pharma, Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Dr. Roseff and his colleagues are conducting a study to evaluate the effectiveness of a novel substance (Inofolic Plus®) in improving oocyte (egg) parameters in subfertile female patients, as measured through Anti-Mullerian Hormone (AMH) blood levels.
Detailed Description
Inofolic Plus® contains several nutritional elements including myo-inositol, melatonin, and folic acid. Myo-inositol was found to be helpful in improving egg quality and/or quantity in women with an ovarian abnormality called polycystic ovarian syndrome as well as in women without the disorder undergoing assisted reproduction. Myo-inositol and folic acid are compounds that belong to the family of B-vitamins. Inositol is normally found in several types of foods. Folic acid has been found to significantly decrease the incidence of certain types of birth defects in women taking sufficient amounts prior to and during pregnancy. Preliminary studies using myo-inositol and folic acid demonstrated improvement in egg quality in-vitro and in-vivo as well as multiple metabolic parameters in women with irregular menstrual cycles and certain types of hormone imbalances. Melatonin is a potent antioxidant. Folic acid is not classified as an antioxidant but has been reported to have antioxidant-like activity. Antioxidants have been given to infertile men for years to improve egg parameters. Most recently, studies have documented the efficacy of antioxidant treatment on human egg parameters and fertilization rates, especially in the setting of in-vitro fertilization (IVF). Inofolic Plus® contains melatonin and folic acid. Dr. Roseff hypothesizes that Inofolic Plus® may be effective in correcting abnormal egg parameters in women. A woman may have abnormal eggs from being exposed to environmental and workplace toxins that generate oxygen free radicals in her body (known as reactive oxygen species, or ROS). These ROS circulate through the blood stream and can enter the ovaries where eggs are stored. Eggs may be sensitive to ROS, and damage from the ROS may result in poor egg quality or quantity or both. The combination of nutrients and antioxidants in Inofolic Plus® may help to correct these abnormalities. Melatonin is a natural hormone normally found in the brain. This hormone helps regulate sleep/wake cycles. Melatonin levels increase during the evening and remain high during the night. This elevated level of melatonin is thought to induce drowsiness. It is because of this effect that we recommend taking Inofolic Plus® in the late evening near bedtime.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Female
Keywords
female fertility, ovarian reserve, oocyte quality, oocyte quantity, antimullerian hormone, AMH, dietary supplements, inofolic plus, myoinositol, folic acid

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inofolic Plus
Arm Type
Experimental
Arm Description
Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Inofolic Plus
Other Intervention Name(s)
folic acid, myoinositol, and melatonin in combination
Intervention Description
Inofolic Plus contains folic acid and myoinositol and melatonin
Primary Outcome Measure Information:
Title
Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve (AMH Levels)
Description
Women will receive Infolic Plus nightly for up to 90 days. Baseline AMH blood levels will be analyzed, and AMH titers will be checked monthly thereafter for the 90 day duration of the study.
Time Frame
Three Months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female between 18 - 42 years of age Diagnosed with "Diminished Ovarian Reserve" (DOR) Exclusion Criteria: Ongoing history of illicit drug or tobacco use Ovarian surgery within 90 days of signing the consent form
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott Roseff, MD
Organizational Affiliation
Palm Beach Center for Reproductive Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Palm Beach Center for Reproductive Medicine
City
Wellington
State/Province
Florida
ZIP/Postal Code
33414
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18339123
Citation
Tamura H, Takasaki A, Miwa I, Taniguchi K, Maekawa R, Asada H, Taketani T, Matsuoka A, Yamagata Y, Shimamura K, Morioka H, Ishikawa H, Reiter RJ, Sugino N. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res. 2008 Apr;44(3):280-7. doi: 10.1111/j.1600-079X.2007.00524.x.
Results Reference
background
PubMed Identifier
18804205
Citation
Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, Reiter RJ. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2009 Jul;92(1):328-43. doi: 10.1016/j.fertnstert.2008.05.016. Epub 2008 Sep 18.
Results Reference
background
PubMed Identifier
18462730
Citation
Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009 May;91(5):1750-4. doi: 10.1016/j.fertnstert.2008.01.088. Epub 2008 May 7.
Results Reference
background
PubMed Identifier
19800728
Citation
Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):120-3. doi: 10.1016/j.ejogrb.2009.09.008. Epub 2009 Oct 2.
Results Reference
background

Learn more about this trial

The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women

We'll reach out to this number within 24 hrs